The findings of this study support the fact that to prevent the incidence of myocardial infarction and stroke caused by atherogenic lipids or inflammation, sufficient additional medication such as metformin or a statin (with protective effects) and not treatment with SGLT2 inhibitors alone, is necessary for patients with diabetes. The gene discussed is SLC5A2; the disease is stroke disorder.